
Bristol Myers to buy schizophrenia drugmaker Karuna Therapeutics for $14 billion By Reuters
By Michael Erman and Manas Mishra (Reuters) -Bristol Myers Squibb on Friday agreed to buy Karuna Therapeutics (NASDAQ:) for $14 billion, gaining a promising